Location History:
- Watlington, GB (1985 - 1987)
- Stevenage, GB (1997 - 2022)
Company Filing History:
4 out of 1,323 
2 out of 1,168 
2 out of 230 
Years Active: 1985-2022
Title: Michael Menteith Hann: Innovator in Targeted Protein Degradation
Introduction
Michael Menteith Hann is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of biotechnology, particularly in the area of targeted protein degradation. With a total of 8 patents to his name, Hann's work is paving the way for advancements in cell and gene therapy.
Latest Patents
Hann's latest patents focus on a method of controlling the level of a polypeptide sequence. This involves administering a polypeptide sequence fused to a ubiquitin targeting protein that comprises a minimal degron structural motif. Notably, the polypeptide sequence includes a chimeric antigen receptor, making this invention particularly useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.
Career Highlights
Throughout his career, Michael Menteith Hann has worked with prominent companies such as Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited. His experience in these organizations has contributed to his expertise in the field of biotechnology and patent development.
Collaborations
Hann has collaborated with several professionals in his field, including Duncan Robert Armour and Brian Evans. These collaborations have likely enriched his work and contributed to the innovative solutions he has developed.
Conclusion
Michael Menteith Hann is a distinguished inventor whose work in targeted protein degradation is making a significant impact in biotechnology. His contributions are essential for the advancement of therapies that can control the activity of chimeric antigen receptors.